Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome  Derek A Haas, M.D., Bruce.

Slides:



Advertisements
Similar presentations
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Advertisements

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial  Åsa Lindholm,
Polycystic ovarian syndrome Obesity and Insulin resistance
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D. 
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Hatem Abu Hashim  Reproductive BioMedicine Online 
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study  Jeff G. Wang, M.D., Richard A. Anderson,
The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome  Silvia Ajossa, M.D., Stefano Guerriero, M.D.,
Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis  Anuja Dokras, M.D., Ph.D., Shari.
Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women  Bruce R. Carr, M.D.,
Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women  Babak Mokhlesi, M.D.,
Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives  George Mastorakos,
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters  Enrico Carmina, M.D., Francesco.
Patient-tailored ovarian stimulation for in vitro fertilization
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome  Sigrun B. Kjøtrød, M.D., Arne.
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome 
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot.
Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Zeev Shoham, M.D.  Fertility and Sterility 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study  A. Nasr  Reproductive BioMedicine Online 
Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome  Héctor F. Escobar-Morreale,
Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral.
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.
Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome  Annie A. Guedikian, B.S.,
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.
The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study  Gwinnett Ladson, M.D., William C. Dodson,
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS)  F. Gonzalez,
Ovulation induction in women with polycystic ovary syndrome
Increased secretion of amylin in women with polycystic ovary syndrome
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity 
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in.
Imran Pirwany, MD, Togas Tulandi, MD  Fertility and Sterility 
Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome  Carlos Moran, M.D.,
Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation.
Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.
Comparison of two doses of metformin (2. 5 and 1
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment  Richard Fleming, Ph.D.,
Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D
Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome 
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Are patients with idiopathic hirsutism (IH) insulin resistant
Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.
Anna Maria Fulghesu, M. D. , Mario Ciampelli, M. D. , Giuseppe Muzj, M
Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome  C.J Glueck, M.D., Ping.
Hyperinsulinemia: not involved in the development of PCO?
Touraj Mahmoudi, M. Sc. , Hamid Gourabi, Ph. D. , Mahnaz Ashrafi, M. D
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome  Mesut Ozkaya, Assistant Professor, Erman Cakal, Specialist, Yusuf.
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome 
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary.
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test  Dimitrios Panidis, M.D., Ph.D., Dimitrios.
Treatment decision trends in the infertility patient journey from 78,958 cycles in a real- world database: impact of age, diagnosis, and year of treatment 
Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome  Basak Yildirim, M.D., Nuran Sabir,
Prospective randomized double-blind trial of the correlation between time of administration and antiestrogenic effects of clomiphene citrate on reproductive.
Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M
Enrico Carmina, M.D., Rogerio A Lobo, M.D.  Fertility and Sterility 
Presentation transcript:

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome  Derek A Haas, M.D., Bruce R Carr, M.D., George R Attia, M.D.  Fertility and Sterility  Volume 79, Issue 3, Pages 469-481 (March 2003) DOI: 10.1016/S0015-0282(02)04800-8

FIGURE 1 Sixty-one obese (BMI >28) women with PCOS were randomized to receive either metformin (500 mg three times per day) or placebo for 34 days. If ovulation had not occurred, patients were continued on the same drug while adding CC 50 mg for 5 days. Ovulation was defined by serum P >8 ng/mL (3). Haas. Metformin effects in women with PCOS. Fertil Steril 2003. Fertility and Sterility 2003 79, 469-481DOI: (10.1016/S0015-0282(02)04800-8)

FIGURE 2 Twenty-seven obese, CC-resistant women with PCOS were randomized to receive metformin (500 mg three times per day) or placebo for 7 weeks. Patients not ovulating during this time continued to take their study drug, while CC 50 mg was added for 5 days. If ovulation did not occur, CC was increased by 50 mg each cycle. Ovulation was defined by serum P >4 ng/mL (23). Haas. Metformin effects in women with PCOS. Fertil Steril 2003. Fertility and Sterility 2003 79, 469-481DOI: (10.1016/S0015-0282(02)04800-8)

FIGURE 3 Twenty lean, CC-resistant women with PCOS were randomized to receive metformin (500 mg three times per day) or placebo for 3 months. If no ovulation had occurred by 3 months, CC 100 mg was added for 5 days. Serum P was measured weekly. Ovulation was defined by serum P >5 ng/mL (24). Haas. Metformin effects in women with PCOS. Fertil Steril 2003. Fertility and Sterility 2003 79, 469-481DOI: (10.1016/S0015-0282(02)04800-8)

FIGURE 4 Twenty CC-resistant women with PCOS were randomized into two groups of 10 each. Group A was stimulated with FSH alone for two cycles and then treated with metformin (500 mg three times per day) for 1 month. For their third cycle, they were treated with both metformin and FSH. Group B was treated with metformin (500 mg three times per day) for 1 month before their one stimulation cycle using both metformin and FSH (25). Haas. Metformin effects in women with PCOS. Fertil Steril 2003. Fertility and Sterility 2003 79, 469-481DOI: (10.1016/S0015-0282(02)04800-8)